HT .I agree with your sentiments that additional value would be best realised by a company other than Acadia Pharmaceuticals .I think the one most likely is Takeda Pharmaceuticals ,who incidentally is 10 times the size of ACAD.They have the firepower and Neuren is right in their wheelhouse .As a shareholder I personally don’t care who buys Neuren as long as the price is right.
Ann: Validation for NNZ-2591 neurodevelopmental disorder pipeline, page-85
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.96 |
Change
-0.140(1.07%) |
Mkt cap ! $1.612B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.36 | $12.82 | $4.627M | 354.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7585 | $12.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.03 | 3344 | 2 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |